NCT05314504已完成不适用
A Multicenter, Randomized, Rater-Blinded, No-Treatment Control Design Clinical Investigation to Evaluate the Effectiveness and Safety of YVOIRE Y-Solution 360 for Lip Augmentation
LG Chem1 个研究点 分布在 1 个国家目标入组 174 人开始时间: 2022年1月11日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 174
- 试验地点
- 1
- 主要终点
- Overall LFRS responder rate
研究概览
简要总结
To evaluate the effectiveness and safety of the investigational medical device, injected into the lips.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male or female adults 18 to 65 years of age (inclusive).
- •Subjects whose volume of the overall lips corresponds to score of 0 (none/minimal), 1 (mild), 2 (moderate), or 3 (pronounced) of the 5-point LFRS as assessed by the blinded Evaluating Investigator at Visit 1 (Screening).
- •Subjects who want a filler injection procedure for at least a 1-grade increase on the overall LFRS score after treatment.
- •Subjects who are informed of the purpose, method, and effectiveness of the clinical investigation and who sign the written informed consent form (ICF).
- •Except for surgically sterile male or female subjects, and female subjects with natural menopause (without drug intervention) for more than 2 years after last menstruation, other male or female subjects must agree to use an effective method throughout the entire clinical investigation period to prevent pregnancy
排除标准
- •Subjects who have lip tattoos, piercings, facial hair, or scars that would interfere with visualization of the lips and perioral area.
- •Subjects who have dentures or any device covering all or part of the upper palate, and/or severe malocclusion or dentofacial or maxillofacial deformities.
- •Subjects who have undergone oral surgery (e.g., tooth extraction, orthodontia, or implantation) within 6 months before enrollment or is planning to undergo any of these procedures during the clinical investigation.
- •Subjects who have received permanent facial implants or fillers (e.g., polymethylmethacrylate, silicone, polytetrafluoroethylene, autologous fat) in the face or neck, or are planning to be implanted with any of these products during the clinical investigation.
- •Subjects who have received non-permanent filler treatment in the lower face (below the orbital rim) or are planning to undergo during the clinical investigation, including but not limited to receiving calcium hydroxylapatite or poly-L lactic acid within 24 months before enrollment, or hyaluronic acid [HA] or collagen within 12 months before enrollment.
- •Subjects who have undergone the following procedure within 6 months before enrollment or are planning to undergo during the clinical investigation: Facial tissue augmentation or facial treatment with fat or botulinum injections in the lower face (below the orbital rim). messotherapy, face lift, stripping laser, dermabrasion, moderate or greater depth chemical peel, or other ablative procedures in face or neck.
- •Subjects who have used non-implantable lip plumping products within 10 days before enrollment anywhere in the treatment area or are planning to receive such treatment/intervention during the clinical investigation participation.
- •Subjects who have used any over-the-counter or prescription, oral or topical anti-wrinkle products for the lips or around the mouth within 3 months before enrollment or are planning to use such products during the clinical investigation.
- •Subjects who are on an ongoing regimen of anti-coagulation therapy (e.g., warfarin) or non-steroidal anti-inflammatory drugs (NSAIDs; e.g., aspirin, ibuprofen) or other substances known to increase coagulation time (e.g., herbal supplements with gingko biloba) within 10 days of undergoing investigational medical device injections.
- •Subjects who have history of anaphylaxis, multiple several allergies, or allergy to lidocaine, or amide local anesthetics, HA products, or Streptococcal protein, or are planning to undergo desensitization therapy during the clinical investigation.
- •Subjects with active inflammation, infection sites or unhealed wound in the mouth area.
- •Subjects who have history of herpetic eruption.
- •Subjects who have history of bleeding disorder based on the coagulation laboratory test results (international normalized ratio [INR], prothrombin time, and activated partial thromboplastin time [aPTT]) as per Investigator's discretion.
- •Subjects with abnormal laboratory assessment and judged clinically significant per Investigator's discretion (e.g., alanine aminotransferase [ALT] ≥ 2.5×upper limit of normal [ULN], aspartate aminotransferase [AST] ≥ 2.5×ULN).
- •Subjects who have porphyria.
- •Subjects who have a tendency to develop hypertrophic scar or keloid.
- •Subjects who have severe cardiovascular, hepatic or renal diseases considered as per Investigator's discretion.
- •Subjects who have malignant tumors or cancerous or precancerous lesion which could affect the clinical investigation.
- •Subjects who have untreated epilepsy.
- •Subjects who are ineligible for this clinical investigation as per Investigator's discretion.
- •Subjects who have participated in another clinical investigation within 1 month prior to Visit 1 (Screening).
结局指标
主要结局
Overall LFRS responder rate
时间窗: at 12 weeks
at 12 weeks after the last injection for the test group and at Week 12 for the control group
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Efficacy and Safety Evaluation Study of Neuramis® Deep Lidocaine in Correction of Nasolabial FoldNasolabial FoldNCT02751034Medy-Tox60
已完成
不适用
Functional Study to Investigate the Efficacy of a New Medical Device (Modified Diprobase Formulation)Dermatitis, AtopicNCT03672383Bayer42
已完成
1 期
Dose-Escalating Multiple Dose Study of PD-0360324 in Combination With Methotrexate in Patients With Rheumatoid ArthritisArthritis, RheumatoidNCT00550355Pfizer78
终止
2 期
Study of Occipital Nerve Stimulation for Drug Refractory MigraineMigraineNCT00747812Boston Scientific Corporation11
终止
1 期
A Multiple Dose Study Of PD-0360324 In Patients With Active Cutaneous Lupus ErythematosusCutaneous Lupus ErythematosusNCT01470313Pfizer28